Zafardoust Simin, Ansaripor Soheila, Karimi Atousa, Hosseinirad Hossein, Ataei Mina
Avicenna Infertility Clinic, Avicenna Research Institute, ACECR, Tehran, Iran.
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Maedica (Bucur). 2022 Jun;17(2):336-343. doi: 10.26574/maedica.2022.17.2.336.
The present study aimed to evaluate the effect of adjuvant growth hormone (GH) therapy in antagonist protocol aiming to improve ovarian response and clinical outcomes of women with poor ovarian response. This clinical trial was a single-center study, controlled with equal randomization, which was carried out in Avicenna Infertility Clinic, Tehran, Iran. Totally, 118 patients were randomly allocated to either the intervention or the control group. The intervention group received GH and gonadotropin in gonadotropin-releasing hormone (GnRH) antagonist protocol (GH/GnRHant), while the control group received gonadotropin in GnRH antagonist protocol (GnRHant). The results revealed that the number of days of gonadotropin administration significantly decreased (p-value = 0.040) in the GH/GnRHant group compared to the GnRHant group. Also, our study findings showed that a number of top-quality day 3 embryos and clinical pregnancy rate were higher in the GH/GnRHant group (p-value = 0.007) compared to the GnRHant group (p-value = 0.036). However, there was no significant difference between the two groups in terms of number of received gonadotropin ampoules, number of retrieved MI and MII oocytes, chemical pregnancy rate, ongoing pregnancy rate and live birth rate. These results suggest that adjuvant GH therapy in antagonist protocol in women with a history of poor ovarian response is effective to decrease the number of days of received gonadotropin ampoules and improve pregnancy rate.
本研究旨在评估辅助生长激素（GH）治疗在拮抗剂方案中的效果，旨在改善卵巢反应不良女性的卵巢反应和临床结局。这项临床试验是一项单中心研究，采用等随机对照，在伊朗德黑兰的阿维森纳不孕诊所进行。总共118例患者被随机分配到干预组或对照组。干预组在促性腺激素释放激素（GnRH）拮抗剂方案中接受GH和促性腺激素（GH/GnRHant），而对照组在GnRH拮抗剂方案中接受促性腺激素（GnRHant）。结果显示，与GnRHant组相比，GH/GnRHant组促性腺激素给药天数显著减少（p值 = 0.040）。此外，我们的研究结果表明，与GnRHant组相比，GH/GnRHant组优质第3天胚胎数量和临床妊娠率更高（p值 = 0.007）（p值 = 0.036）。然而，两组在接受的促性腺激素安瓿数量、回收的MI和MII卵母细胞数量、化学妊娠率、持续妊娠率和活产率方面没有显著差异。这些结果表明，对于有卵巢反应不良病史的女性，在拮抗剂方案中辅助GH治疗可有效减少促性腺激素安瓿的给药天数并提高妊娠率。
